HIMS241122C15500
- 5.48
- +1.40+34.31%
Hims & Hers Health Newsroom
BofA Securities Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Cuts Target Price to $18
Hims & Hers Health Analyst Ratings
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $28
Hims & Hers Health Analyst Ratings
Hims & Hers Health Is Maintained at Hold by Deutsche Bank
Deutsche Bank Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $27
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $24 to $32
Hims & Hers Health: Balancing Strong Performance With Regulatory Uncertainty – Hold Rating Maintained
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)
Hims & Hers Health Is Maintained at Buy by Canaccord Genuity
Hims & Hers Health Price Target Raised to $28.00/Share From $24.00 by Canaccord Genuity
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $21 to $28
Hims & Hers Health Analyst Ratings
Ryan MacDonald's Buy Rating on Hims & Hers Health Driven by Strong Performance and Strategic Initiatives
Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), Avanos Medical (AVNS) and Alphatec Holdings (ATEC)
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $25
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $26
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $25